ME00945B - UPOTREBA PREPARATA KOJI SADRŽI FORMOTEROL I BEKLOMETAZON DIPROPIONAT ZA PREVENCIJH l/ILI LEČENJE POGORŠANJA STANJA KOD ASTME - Google Patents

UPOTREBA PREPARATA KOJI SADRŽI FORMOTEROL I BEKLOMETAZON DIPROPIONAT ZA PREVENCIJH l/ILI LEČENJE POGORŠANJA STANJA KOD ASTME

Info

Publication number
ME00945B
ME00945B MEP-2009-315A MEP31509A ME00945B ME 00945 B ME00945 B ME 00945B ME P31509 A MEP31509 A ME P31509A ME 00945 B ME00945 B ME 00945B
Authority
ME
Montenegro
Prior art keywords
asthma
formoterol
composition
exacerbation
prevention
Prior art date
Application number
MEP-2009-315A
Other languages
English (en)
French (fr)
Inventor
Paolo Chiesi
Ivano Rondelli
Daniela Acerbi
Gianluigi Poli
Original Assignee
Chiesi Farm Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38458097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ME00945(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farm Spa filed Critical Chiesi Farm Spa
Publication of ME00945B publication Critical patent/ME00945B/me

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

Predmetni pronalazak se odnosi na upotrebu preparata koji sadrži kombinaciju nepromenljivih udela a) formoterola, njegove farmaceutski prihvatljive soli ili solvata, ili solvata takve soli i b) beklometazon dipropionata za proizvodnju leka koji se koristi u prevenciji i/ili lečenju pogoršanja stanja kod astme, povremenih napada astme i/ili epizoda kod hroničnih astmatičnih stanja, u toku terapije za održavanje stanja kod astme istim preparatom, za olakšanje simptoma, po potrebi. 
MEP-2009-315A 2007-04-19 2008-04-16 UPOTREBA PREPARATA KOJI SADRŽI FORMOTEROL I BEKLOMETAZON DIPROPIONAT ZA PREVENCIJH l/ILI LEČENJE POGORŠANJA STANJA KOD ASTME ME00945B (me)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07007930A EP1982709A1 (en) 2007-04-19 2007-04-19 Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
PCT/EP2008/003012 WO2008128685A1 (en) 2007-04-19 2008-04-16 Use of a composition comprising formoterol and beclometasone dipropionate for the prevention and/or treatment of an exacerbation of asthma

Publications (1)

Publication Number Publication Date
ME00945B true ME00945B (me) 2012-06-20

Family

ID=38458097

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2009-315A ME00945B (me) 2007-04-19 2008-04-16 UPOTREBA PREPARATA KOJI SADRŽI FORMOTEROL I BEKLOMETAZON DIPROPIONAT ZA PREVENCIJH l/ILI LEČENJE POGORŠANJA STANJA KOD ASTME

Country Status (30)

Country Link
US (1) US20080261932A1 (me)
EP (3) EP1982709A1 (me)
JP (2) JP5492072B2 (me)
KR (3) KR101621676B1 (me)
CN (1) CN101657191B (me)
AU (1) AU2008241045C1 (me)
BR (1) BRPI0809800A2 (me)
CA (1) CA2684539A1 (me)
CO (1) CO6220945A2 (me)
CY (1) CY1117568T1 (me)
DK (1) DK2146704T3 (me)
EA (1) EA018589B1 (me)
ES (2) ES2740103T3 (me)
GE (1) GEP20145999B (me)
HK (1) HK1137357A1 (me)
HR (1) HRP20160588T1 (me)
HU (1) HUE029263T2 (me)
IL (1) IL201632A (me)
MA (1) MA31315B1 (me)
ME (1) ME00945B (me)
MX (1) MX2009010851A (me)
MY (1) MY169579A (me)
NZ (1) NZ580526A (me)
PL (2) PL3034073T3 (me)
RS (1) RS54874B1 (me)
SI (1) SI2146704T1 (me)
TN (1) TN2009000390A1 (me)
TR (1) TR201909857T4 (me)
UA (1) UA100237C2 (me)
WO (1) WO2008128685A1 (me)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma
ME02398B (me) * 2009-10-02 2016-09-20 Chiesi Farm Spa Farmaceutske aerosolne formulacije formoterola i beklometazon dipropionata
CN102247597B (zh) * 2010-05-19 2015-01-07 天津金耀集团有限公司 一种糖皮质激素与支气管扩张剂的吸入剂
KR101560288B1 (ko) * 2012-01-25 2015-10-14 키에시 파르마슈티시 엣스. 피. 에이. 흡입에 의한 투여를 위한 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제
US11052202B2 (en) * 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
PE20191044A1 (es) * 2016-09-19 2019-08-06 Mexichem Fluor Sa De Cv Composicion farmaceutica
CN107233311B (zh) * 2017-06-27 2020-12-04 长风药业股份有限公司 一种以阿福特罗和格隆溴铵为活性成分的雾化剂及其制备方法
WO2024097413A1 (en) * 2022-11-03 2024-05-10 Dana-Farber Cancer Institute, Inc. Methods of treating anemia using formoterol or a pharmaceutically acceptable salt thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
AU673660C (en) 1991-12-18 2002-07-25 Astrazeneca Ab New combination of formoterol and budesonide
SE9802073D0 (sv) * 1998-06-11 1998-06-11 Astra Ab New use
JP5392880B2 (ja) 2000-05-22 2014-01-22 キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ 加圧式定量吸入器のための安定な製薬学的溶液製剤
FI20002177A0 (fi) * 2000-10-02 2000-10-02 Orion Yhtymae Oyj Uusi yhdistelmä astman hoitoon
FI20002216A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit astman hoitoon
FI20002215A0 (fi) * 2000-10-06 2000-10-06 Orion Yhtymae Oyj Yhdistelmäpartikkelit
KR100947409B1 (ko) 2002-03-01 2010-03-12 키에시 파르마슈티시 엣스. 피. 에이. 포모테롤 초미세 조성물
EP1982709A1 (en) * 2007-04-19 2008-10-22 CHIESI FARMACEUTICI S.p.A. Use of a composition comprising formoterol and beclomethasone dipropionate for the prevention or treatment of an acute condition of asthma

Also Published As

Publication number Publication date
MX2009010851A (es) 2009-11-05
CY1117568T1 (el) 2017-04-26
CN101657191A (zh) 2010-02-24
ES2740103T3 (es) 2020-02-05
CN101657191B (zh) 2014-06-11
GEP20145999B (en) 2014-01-10
IL201632A (en) 2016-09-29
SI2146704T1 (sl) 2016-05-31
EP3034073A1 (en) 2016-06-22
ES2568497T3 (es) 2016-04-29
TR201909857T4 (tr) 2019-07-22
EA200901201A1 (ru) 2010-04-30
PL3034073T3 (pl) 2019-11-29
PL2146704T3 (pl) 2016-09-30
MA31315B1 (fr) 2010-04-01
EA018589B1 (ru) 2013-09-30
AU2008241045C1 (en) 2023-06-15
BRPI0809800A2 (pt) 2014-10-07
HUE029263T2 (en) 2017-02-28
US20080261932A1 (en) 2008-10-23
AU2008241045B2 (en) 2013-06-20
KR101621676B1 (ko) 2016-05-16
HK1137357A1 (en) 2010-07-30
KR20100014408A (ko) 2010-02-10
MY169579A (en) 2019-04-22
KR101668203B1 (ko) 2016-10-20
EP2146704B1 (en) 2016-03-23
JP5492072B2 (ja) 2014-05-14
NZ580526A (en) 2012-07-27
TN2009000390A1 (en) 2010-12-31
CA2684539A1 (en) 2008-10-30
JP2010524873A (ja) 2010-07-22
IL201632A0 (en) 2010-05-31
EP2146704A1 (en) 2010-01-27
UA100237C2 (uk) 2012-12-10
JP2014005312A (ja) 2014-01-16
KR20150082699A (ko) 2015-07-15
KR20150038618A (ko) 2015-04-08
EP1982709A1 (en) 2008-10-22
HRP20160588T1 (hr) 2016-07-01
WO2008128685A1 (en) 2008-10-30
RS54874B1 (sr) 2016-10-31
CO6220945A2 (es) 2010-11-19
DK2146704T3 (en) 2016-05-23
AU2008241045A1 (en) 2008-10-30
EP3034073B1 (en) 2019-06-12

Similar Documents

Publication Publication Date Title
ME00945B (me) UPOTREBA PREPARATA KOJI SADRŽI FORMOTEROL I BEKLOMETAZON DIPROPIONAT ZA PREVENCIJH l/ILI LEČENJE POGORŠANJA STANJA KOD ASTME
UY32989A (es) Coposiciones terapéuticas concentradas de fosfolípidos
BR112014029442A2 (pt) composições antimucosas à base de xilitol e métodos e composições relacionados
EP2749280A3 (en) Combination of glycopyrronium and formoterol
MX337454B (es) Composicion acuosa que contiene bromhexina.
CL2011002787A1 (es) Compuestos derivados de 1-cianoetilheterociclilcarboxamida sustituidos, inhibidores de dipeptidilpeptidasa i (dppi) o catepsina c; composicion farmaceutica; combinacion faramceutica; y su uso en el tratamiento del asma, la enfermedad obstructiva cronica o la rinitis alergica.
MA38276B1 (fr) Dérivés de l'exendine 4 pour l’utilisation dans le traitement des troubles du syndrome metabolique, y compris le diabete et l'obesite, ainsi que la reduction de l'apport alimentaire excessif.
BR112013002601A2 (pt) corticosteróides para o tratamento de dor em articulação
NO20073254L (no) Sammensetninger omfattende ornitin og fenylacetat eller fenylbutyrat for a behandle hepatisk encefalopati
CR11418A (es) Trans-clomifeno para el sindrome metabolico
BRPI1008227A8 (pt) composição de glicocorticoide inalável para uso na terapia de um paciente que sofre de asma severa e sem controle.
BR112013008974A2 (pt) Composição farmacêutica, processo para fabricar uma composição farmacêutica e uso de uma composição farmacêutica
NO341676B1 (no) Tetrahydro-pyrimidoazepiner som modulatorer av TRPVI
ECSP11010925A (es) Partículas inhalables que comprenden tiotropio
BRPI0911469A8 (pt) Inibidores de gm-csf e il-17 para terapia
EA201290374A1 (ru) Аэрозольная композиция для copd
TR201000733A2 (tr) Flutikazon, tiotropyum ve sodyum kromoglikat içeren farmasötik bileşimler.
BR112016002317A8 (pt) Uso de benralizumab ou de um seu fragmento de ligação ao antígeno para aumentar o volume expiratório forçado em asmáticos e benralizumab ou de um seu fragmento de ligação ao antígeno para uso para aumentar o volume expiratório forçado em asmáticos
CL2008000973A1 (es) Compuestos derivados de 1-oxo-isoquinolina; procedimiento de preparación; composición farmacéutica; y su uso en el tratamiento de enfermedades pulmonares obstructvas crónicas (epoc) y asma.
BR112015001627A2 (pt) composição farmacêutica, respectivos usos e método para diminuir a frequência de micção
ECSP088588A (es) Uso de sales de tiotropio en el tratamiento del asma persistente moderada
WO2012165810A3 (ko) 오고닌을 유효성분으로 함유하는 천식 예방 또는 치료용 약학적 조성물
TR200907913A2 (tr) İnhalason yolu ile alınmak üzere kuru toz formunda farmasötik bileşim
MX2009002717A (es) Composiciones y metodos para tratamiento del sindrome de fatiga cronica y enfermedades neurodegenerativas.
NO20083890L (no) Pakningsanordning for flerdoseinhalatorer med optimaliserte utslippsegenskaper